Utah State University

DigitalCommons@USU
All Graduate Theses and Dissertations

Graduate Studies

5-2010

Arterial Oxygen Saturation as a Predictor of Acute Mountain
Sickness and Summit Success among Mountianeers
Jonathan R. Knott
Utah State University

Follow this and additional works at: https://digitalcommons.usu.edu/etd
Part of the Medicine and Health Sciences Commons

Recommended Citation
Knott, Jonathan R., "Arterial Oxygen Saturation as a Predictor of Acute Mountain Sickness and Summit
Success among Mountianeers" (2010). All Graduate Theses and Dissertations. 674.
https://digitalcommons.usu.edu/etd/674

This Thesis is brought to you for free and open access by
the Graduate Studies at DigitalCommons@USU. It has
been accepted for inclusion in All Graduate Theses and
Dissertations by an authorized administrator of
DigitalCommons@USU. For more information, please
contact digitalcommons@usu.edu.

ARTERIAL OXYGEN SATURATION AS A PREDICTOR OF ACUTE MOUNTAIN
SICKNESS AND SUMMIT SUCCESS AMONG MOUNTAINEERS

by

Jonathan R. Knott

A thesis submitted in partial fulfillment
of the requirements for the degree
of
MASTER OF SCIENCE
in
Health and Human Movement
Approved:

––––––––––––––––––––––––
Dale R. Wagner, PhD
Major Professor

––––––––––––––––––––––––
Edward M. Heath, PhD
Committee Member

––––––––––––––––––––––––
James Davis, MD
Committee Member

––––––––––––––––––––––
Byron R. Burnham, EdD
Dean of Graduate Studies

UTAH STATE UNIVERSITY
Logan, Utah
2010

ii

Copyright

Jonathan Knott 2010

All Rights Reserved

iii
ABSTRACT

Arterial Oxygen Saturation as a Predictor of Acute Mountain Sickness and
Summit Success among Mountaineers

by

Jonathan R. Knott, Master of Science
Utah State University, 2010

Major Professor: Dr. Dale R. Wagner
Department: Health, Physical Education and Recreation
The purpose of this study was to determine if arterial oxygen saturation (SaO2), as
measured by a finger pulse oximeter upon rapid arrival to 4260 m, could be predictive of
acute mountain sickness (AMS) or summit success on a climb to 5640 m. In total 73
climbers volunteered to participate in the study. After excluding those taking drugs to
counteract the effects of AMS and those with missing data, 48 participants (45 male, 3
female) remained. Climbers were transported from 2650 m to the Piedra Grande hut at
4260 m on Pico de Orizaba within 2 hr. After a median time of 10 ± 13 hr at the hut, they
climbed toward the summit (5640 m) and returned with a median trip time of 13.3 ± 4.8
hr. The Lake Louise Self-assessment Questionnaire (LLSA) for AMS, heart rate, and
SaO2 from a finger pulse oximeter was collected upon arrival at the hut, repeated
immediately before the climbers departed for their summit attempts, and immediately
upon their return. The presence of AMS was defined as a LLSA score ≥ 3 with a
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headache and at least one other symptom. Fifty-nine percent of the participants
successfully reached the summit. Average SaO2 for all participants at 4260 m prior to
their departure for the summit was 84.2 ± 3.8%. Sixty percent of the participants met the
criteria for AMS during their ascent. There was not a significant difference (p = .90) in
SaO2 between those who experienced AMS (SaO2 = 84.3 ± 3.3%) and those who did not
(SaO2 = 84.2 ± 4.2%) during the ascent. Neither was there a significant difference (p =
.18) in SaO2 between those who reached the summit (84.8 ± 3.7%) and those who did not
(83.3 ± 4.0%). Arterial oxygen saturation does not appear to be predictive of AMS or
summit success.
(71 pages)
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DEFINITIONS OF TERMS

Acclimatization: Process of becoming physiologically adapted to hypoxic conditions.
Acute Mountain Sickness (AMS): Experiencing a headache along with several other
symptoms such as dizziness, fatigue, gastrointestinal problems, and difficulty
sleeping which result from the hypoxic conditions while at high altitude.
Arterial Oxygen Saturation (SaO2): Percentage of oxygen bound to hemoglobin within
the arterial blood.
Dalton’s Law: The total pressure exerted by a gaseous mixture is equal to the sum of the
partial pressures of each of the component gasses.
Finger Pulse Oximetry: Noninvasive method of measuring the percentage of arterial
blood oxygen saturation by measuring the absorption of light-emitting diodes
(LEDs) at different wavelengths.
Henry’s Law: At constant temperature, the amount of a gas dissolved into a given volume
is directly proportional to the partial pressure of the gas.
High Altitude: Generally considered to be 1500-3500 m; very high altitude is from 35005500 m; extreme altitude is > 5500 m.
Hypoxemia: Deficient oxygenation of the blood.
Hypoxic Ventilatory Response (HVR): Altered rate of ventilation induced by hypoxia.
Impaired Pulmonary Exchange (IPE): When a stimulus of internal or external origin
elicits a reduction in gas exchange between the tissues of the pulmonary system.
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Lake Louise Self-Assessment (LLSA): Questionnaire for determining the severity of
AMS by quantifying the climber’s self-reported perception of the severity of
symptoms.
Visual Analogue Scale (VAS): Subjective continuous scale consisting of a solid line
where one side represents ”none” and the other represents ”severe or maximal.”
Participants are asked to place a mark on the line that best represents their
perceived level of discomfort.

CHAPTER 1
INTRODUCTION

Men and women have always been drawn to the power and mystery of the
mountains. The greatest giant of them all, Mt. Everest, has stood as an inspiration to
many as the ultimate accomplishment, though for many years it seemed insurmountable.
It was not until 1953 that Edmund Hillary and Tenzing Norgay were able to take the final
steps to reach the highest point on the planet. People are traveling to new and
adventurous places at an ever-increasing rate. To satisfy this drive for adventure, the
limits of the human body are constantly being pushed. Heights previously thought to be
unconquerable are being conquered. These new ventures into the unknown are always
greeted with unexpected trials that necessitate unique solutions.
In addition to the physical demands that excursions such as Hillary’s present,
there are also many physiological limitations to the human body as well. These negative
effects have been recorded as early as Plutarch’s writings of Alexander’s army crossing
into India in 326 BC. Associated with these and other writings have been descriptions of
headache, intestinal discomfort, and fatigue. Today, a collective term used for the many
adverse symptoms associated with high altitude travel is acute mountain sickness (AMS).
As much as ever, AMS is a common diagnosis among those who reach high altitudes.
Those unfortunate enough to experience AMS can expect to endure a great deal of
discomfort. Due to these inherent consequences, AMS can seriously alter expedition
plans and put an end to the possibility of human achievement.
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Significance of Study

As a result of the severity of AMS and the wide spread potential for negative
outcomes, it is essential that this syndrome be better understood. A great deal of recent
research has been dedicated to this end. Much of this research is aimed toward the use of
arterial oxygen saturation (SaO2) as a means of predicting future susceptibility to AMS
upon further ascent. By conducting further research, a better understanding of the
physiological responses to altitude that directly attribute to this syndrome will be gained.
If pulse oximetry can be found affective at predicting AMS it would provide a
quantitative measurement rather than just a subjective measurement. This could
potentially revolutionize the diagnosis of AMS. Results from previous research show
potential for pulse oximetry in predicting AMS (Burtscher, Flatz, & Faulhaber, 2004;
Burtscher, Szubski, & Faulhaber, 2008; Koehle, Guenette, & Warburton, 2010; Roach,
Greene, Schoene, & Hackett, 1998; Tannheimer et al., 2009), but the relationship
between SaO2 and AMS is still not well defined.
Two potentially major influences in the relationship between SaO2 and AMS are
the altitude at which a study is conducted and the duration of hypoxic exposure. To date
most SaO2 research has been conducted at an altitude of around 4000 m while the
duration of hypoxic exposure has varied. The majority of conclusions from this collection
of efforts have stated that alterations in these two factors are what allow, or refuse to
allow, SaO2 predictions of AMS to be possible. A major roadblock for this theory
however, is the lack of studies that focus on the alteration of these variables.
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This study provided a unique opportunity to observe the changes in SaO2 with
increasing duration of hypoxic exposure while relating that change to AMS prediction.
This required a distinctive environment where participants could rapidly gain elevation
while measurements were collected over a period of several days. Few places in the
world allow for this style of data collection; Pico de Orizaba in Mexico is one of these
places. Not only does this location lend itself well to the study of SaO2 and AMS, but it
also allows for a more in depth look at the possible connection between SaO2
measurements and their impact on the summit success of mountaineers. Conducting this
unique study provided a great deal of new insight into these critical relationships that can
potentially lead to better treatments of the direct physiological mechanisms attributed to
AMS and to faster recoveries. In addition, the knowledge learned may translate into
fewer cases and earlier predictions of this syndrome.

Purpose of Study

The purpose of this study was to travel to an atypical location, Pico de Orizaba
Mexico, to study the relationship between AMS and SaO2. In order to perform this study,
the Lake Louise Self-assessment (LLSA) of AMS (Roach, Bartsch, Oelz, & Hackett,
1993) was utilized to compare AMS onset with SaO2 measurements. These SaO2
measurements were recorded prior to AMS onset by finger pulse oximetry at 4260 m.
This comparison has led to a better understand of the relationship between AMS and
SaO2.
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Research Questions

1. Is SaO2 measured by finger pulse oximetry at 4260 m predictive of individual
susceptibility to the later development of AMS?
2. Is SaO2 measured by finger pulse oximetry at 4260 m predictive of summit
success in mountaineers who are making a summit attempt the following day on a
5640 m peak?

Hypotheses

1. A low (< 84%) SaO2 measured by finger pulse oximetry at 4260 m will predict a
mountaineer’s susceptibility to AMS upon further ascent.
2. A low (< 84%) SaO2 measured by finger pulse oximetry at 4260 m will also
predict a mountaineer’s inability to successfully reach the summit on a 5640 m
peak.

Limitations

1. Measurements made by the use of pulse oximetry directly reflect the percentage
of blood oxygen. As a result, these measurements do not directly represent an
individual’s rate of ventilation, as there are a great number of other variables.
2. Pulse oximetry measurements do not give any indication as to the degree of
oxygen metabolism on the cellular level. It is therefore possible for oxygen
saturation levels to be high while cells are experiencing a reduced rate of oxygen
metabolism in response to many possible variables.
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3. Number of participants was limited to the number of willing mountaineers
attempting to summit during the data collection period.
4. Questionnaire type assessments, such as the LLSA, have a strongly subjective
influence that can interfere with AMS diagnosis.

Delimitations

1. Due to the harsh conditions of this study, assessments of AMS severity during the
climbers’ attempts to summit the mountain were not possible. As a result of this
complication, post ascent questionnaires were rephrased to report how the
participants felt during their ascent.
2. In addition to the inability to collect AMS assessments, measurements of SaO2
were also not possible during the ascents above 4260 m. These measurements
were, however, taken immediately upon the return of climbers from their attempts
to summit the mountain.
3. As all who arrived to the mountain hut wished to make an attempt to reach the
summit, participants of this study were their own control. There was no assigned
group receiving no treatment.

Assumption

LLSA will correctly diagnose AMS.
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CHAPTER 2
REVIEW OF LITERATURE

The increasing prevalence of high altitude adventure and travel has lead to a need
for the improvement of AMS prediction and prediagnosis. This review will discuss the
relevant background and research associated with AMS and the use of pulse oximetry as
a diagnostic tool. The presentation of these findings has been structured into the
following categories: (a) acute mountain sickness, (b) techniques for the assessment of
acute mountain sickness, (c) pulse oximetry, (d) use of SaO2 for the prediction of acute
mountain sickness, and (e) summary.

Acute Mountain Sickness

Acute mountain sickness is frequently diagnosed in unacclimatized individuals
who ascend to 2300 m of altitude or higher. Studies have shown upwards of 25% of
travelers experience the symptoms of AMS (Basnyat, Lemaster, & Litch, 1999). The
symptoms and their severity can vary to the degree of altitude to which they are trying to
achieve and are a result of the many physiological responses to a hypoxic environment.
At high altitude, there is a combined effect of Dalton’s Law and Henry’s Law. These
laws describe the low partial pressure of oxygen that exists in the high altitude
environment. Human exposure to these hypoxic conditions causes oxygen transport
between blood and tissue to be reduced. This reduction is the result of the pressure
gradient between oxygen in the alveoli, arterial blood, and tissues all approaching zero.
The total effect of these processes means less oxygen available for utilization by the
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body. These effects are collectively referred to as hypoxemia. Further responses to
hypoxemia force the cardiopulmonary system to work harder so as to overcome the
oxygen deficit by pumping a greater volume of blood through the lungs as well as
moving more air in and out. This increase in the volume of air through the lungs is
referred to as the hypoxic ventilatory response (HVR).
Initial responses to hypoxia often lead to further physiological changes that can
result in the recognizable symptoms of AMS. These characteristic symptoms can include
headache, fatigue, drowsiness, lack of appetite, and gastrointestinal distress. There are
many specific internal and external factors that have been theorized to play important
roles toward the onset of AMS. External factors include the rate and extent to which
altitude is achieved. Ascending at faster rates and higher altitudes increases the
prevalence of AMS. An ideal strategy for acclimatization involves ascending at a rate no
greater then 600 m per 24 hr when above 2500 m and for every increase of 600 to 1200 m
above this altitude, an extra day of acclimatization should be added (Hackett & Roach,
2001). This process of slow ascent allows for the body to adjust to the changing
conditions with altitude in a gradual manner. Presently, research indicates that those with
a history of AMS susceptibility may be at an increased risk while exposed to high altitude
conditions (Wagner, Fargo, Parker, Tatsugawa, & Young, 2006). This theory suggests,
with a high degree of probability, that individual internal, genetically influenced
physiological characteristics common among those of similar ethnicities or among the
same family or even population must play a significant role in the onset of AMS. Current
epidemiological evidence from research studying the relationship of families and

8
populations to AMS susceptibility is in support of this idea (Rupert & Koehle, 2006;
Wang, Koehle, & Rupert, 2009). Examples of genetically influenced internal factors that
may lead to AMS susceptibility include predispositions to diseases such as sickle cell
anemia or even an individual’s cranial capacity to accommodate an increase in cerebral
blood volume and brain water levels throughout the edemic response to hypoxemia
(Hackett & Roach, 2001). If the symptoms of AMS are ignored and ascent is continued,
climbers will risk developing more serious and life-threatening conditions. High altitude
cerebral edema (HACE) is thought to be an end stage of AMS (Hackett & Roach, 2001)
and can lead to severe impairment and death if untreated.
Current treatment for AMS is highly generalized, as the direct physiological
mechanisms are not fully understood. Common resolutions involve ceasing ascent and
often a descent in altitude until symptoms resolve. Often, oxygen therapy is implemented
in hopes of overcoming the hypoxic conditions, so as to lead to a quicker resolution of
symptoms. Additionally, acetazolamide and dexamethasone have been used in the
treatment and prophylaxis of AMS. Other drug treatments for AMS include the use of
nonsteroidal anti-inflammatory drugs. Such nonsteroidal anti-inflammatory drugs include
aspirin for the prevention of headache and ibuprofen for the treatment of headache
(Hackett & Roach, 2001). In one study, a dose of 400 mg of ibuprofen eliminated
symptoms of headache associated with high altitude (Broome, Stoneham, Beeley,
Milledge, & Hughes, 1994). In another study, prophylactic aspirin taken every four hours
significantly reduced the occurrence of headache while at altitude (Burtscher, Likar,
Nachbauer, & Philadelphy, 1998).
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Techniques for AMS Assessment

In response to the need for diagnosis and ability to quantify the severity of
individual cases of AMS, several assessments have been developed. Two common forms
are the Lake Louise Self-assessment (LLSA) and the Environmental Systems
Questionnaire (ESQ). The LLSA was first published in Hypoxia and Mountain Medicine,
which was compiled by the collaborative effort of the 7th International Hypoxia
Symposium held in Lake Louise, Canada in February of 1991. The contribution of the
LLSA is due to the work of Robert Roach and colleagues (1993). In addition to a
questionnaire of reported AMS symptom severity, this extensive version of the LLSA
also involves the judgment of a physician. There is however, a simpler version of the
LLSA that bases its diagnosis solely on the self-reported severity of headache,
gastrointestinal symptoms, fatigue and/or weakness, dizziness / lightheadness, and
difficulty of sleeping. Each symptom is rated on a scale of 0, meaning none at all, to 3,
implying severe. AMS is diagnosed if an individual presents with a headache, at least one
other symptom, and a total combined score of 3 or higher.
A second common questionnaire, the ESQ, was originally designed to be an
inventory of the 52 physiological and psychological symptoms to expect when traveling
to altitude and did not include a rating scale (Kobrick & Sampson, 1979). Later versions
of the ESQ evolved to include a scale for scoring the individual severity of AMS cases
(Sampson & Kobrick, 1980). The most recent revision termed the ESQ III (Sampson,
Cymerman, Burse, Maher, & Rock, 1983) now includes 67 items and an AMS rating
scale. Current research has suggested that the ESQ III may be equally effective in
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diagnosing AMS if limited to items pertaining to cerebral function only (Beidleman,
Muza, Fulco, Rock, & Cymerman, 2007); thereby simplifying the administration process
of the ESQ III.
Consequences of the inherent characteristics of AMS susceptibility require
expeditions to harsh conditions if accurate field studies are to be produced. The
proliferation of questionnaire type assessments such as the LLSA and the ESQ have been
in large part due to the ease of their field implementation. Assessments that utilize little to
no equipment and can be done in a quick, safe manner are an obvious choice. Often the
fulfillment of these requirements can outweigh inherent, minor, faults in methodology as
obtaining some result is often better than no result. One such fault of these questionnairetype assessments is the dependency on the subjective judgments of the participants. The
process of quantifying self-reported symptoms can become extremely unclear when
attempting to compare diagnosis between individuals due to their differences in
perception of sensations such as pain. Medical professionals have dealt with the issue of
subjectivity in their field by implementing tools such as the visual analog scale (VAS).
Gallagher, Bijur, Latimer, and Silver (2002) reported the use of a VAS as a means of
quantifying the subjective idea of pain. The use of scales such as this has begun to arise
in altitude research for the assessment of headache severity while at altitude (Harris,
Wenzel, & Thomas, 2003), but little is known as to the correlation of these scales with
AMS. Recently, a novel idea proposed the implementation of a version of the VAS in
conjunction with questionnaire-type assessments as an effort to remove some level of
subjectivity and to better understand the correlation between the differing methods of
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assessment (Wagner, Parker, Tatsugawa, & Young, 2007). Wagner et al. reported that the
VAS does, in fact, significantly correlate with the LLSA for AMS. Future research in this
area could greatly simplify and improve current methods of AMS assessment.

Pulse Oximetry

Pulse oximetry refers to the process of measuring the saturation levels of oxygen
bound to hemoglobin within red blood cells. These measurements are made possible by
passing infrared and red light wavelengths through an extremity of the body. The two
wavelengths have different levels of absorption and transmission depending on the
saturation level of hemoglobin. The desaturation of oxygen within the blood results in an
increase of infrared light transmission and a decrease of red light transmission
(Severinghaus & Honda, 1978). A comparison of these two rates of absorption provides a
percentage of oxygen saturation within the arterial blood supply.
The idea of utilizing pulse oximetry for SaO2 measurements began to appear in
the early 1970s. Takuo Aoyagi is credited with the breakthrough idea of measuring
changes in light transmission and using these measurements to calculate SaO2. While
relying on the differences between these transmissions rather than the intensity of
individual transmissions in his calculations, he realized that these changes could only
result from the variations within the blood (Severinghaus & Honda, 1978). This method
eliminated the influence of different tissue densities between individuals on SaO2
measurements and made accurate pulse oximetry possible.
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Since its inception, pulse oximetry has become common practice in the medical
profession. There has grown a great deal of dependence upon pulse oximetry in situations
such as operating rooms. In cases such as this, patients are sedated and may be incapable
of self-regulating oxygen saturation. These measurements allow for physicians to
accurately monitor saturation levels and safely perform necessary procedures. In addition
to its implementation in the field of medicine, the development of portable oximeters has
led to the possible application of the oximeter in a diverse variety of situations.

SaO2 Prediction of AMS
Exposure to high altitude creates hypoxic conditions, which have been shown to
be directly related to SaO2 levels (Burtscher et al., 2008). The occurrence of AMS is also
a direct response to these hypoxic conditions. Based on this close association between
SaO2 and AMS, pulse oximetry measurements have often been thought of as a possible
means of AMS prediction and diagnosis. Physiological responses to hypoxia such as a
reduced HVR or impaired pulmonary exchange (IPE) would result in a theoretical decline
of SaO2. This decline could be easily and accurately measured with the use of a pulse
oximeter. The critical implication is that the symptoms of AMS must be a secondary
response directly attributed to the reduced SaO2 and not simply occur in conjunction with
a declining SaO2 value. If a significant relationship were proven to exist, and the
conditions which allow for such a relationship were explicitly known, then the
measurement of SaO2 would be a powerful predictor of future AMS development. These
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measurements would also be a critical component in providing the quantifiable
objectivity that is currently lacking from other AMS assessments.
The issue that still remains, however, is that the relationship existing between
SaO2 and AMS is highly uncertain. In a recently published article investigating this
relationship, AMS susceptibility and SaO2 were compared in 150 climbers (Burtscher et
al., 2004). Of the 150, 63 were precategorized as susceptible to AMS (AMS+) by
reporting to have experienced AMS on two or more previous occurrences while exposed
to hypoxic conditions. The other 87 climbers were precategorized as nonsusceptible to
AMS (AMS-) as a result of having multiple episodes of hypoxic exposure with no
reported AMS symptoms. The researchers defined past diagnosis of AMS as
experiencing a headache in addition to at least one other symptom from the LLSA scale
during past hypoxic exposures. Altitude of exposure of the study ranged from 2000 m to
4000 m and was quickly induced through the use of helicopters, cable cars, and/or
hypobaric chambers. Immediately upon hypoxic exposure, participants were seated in a
resting position. Twenty to 30 min after initiating the exposure, SaO2 measurements were
taken using a pulse oximeter. The SaO2 of the AMS+ group was compared to the SaO2 of
the AMS- group. The results of this study show that at low altitude (600 m) the SaO2 of
both groups were the same. Furthermore, after exposure to high altitude the SaO2 of the
AMS+ group was 4.9% lower than the AMS- group. Based on the derived model, 86% of
the AMS+ group could be correctly predicted by their SaO2 measurements.
From this study (Burtscher et al., 2004), it was also concluded that the decline of
the HVR is not given significant consideration when exposure time is limited in study

14
design; therefore, implying the importance of studying the HVR in relationship to short
term hypoxic exposure and the onset of AMS. Also reported was the finding of most
significant differences between AMS+ and AMS- at induced altitudes between 3000 m
and 4000 m, indicating an optimal altitude for future research to be conducted. Another
interesting statement made by this study was that they did not attribute low SaO2 to IPE,
as can be a common conclusion under these conditions. Due, in part, to this implication
the researchers were left to ask how much exposure time as well as what degree of
altitude are necessary for an IPE response? Also suggested as the reason for the
discrepancy between findings of a relationship verses no relationship between SaO2 and
AMS were the duration of hypoxic exposure. Summarized were the studies with a short
duration of exposure (hours to days), which usually find no relationship, while studies of
extended exposure (days to weeks) tended to be more apt at deciphering the existence of
a significant relationship. A combination of these conclusions leads to the necessity of
deciphering the AMS onset timeline in relation to the interconnected pathways of
different physiological hypoxic responses.
Additional insight into the SaO2 and AMS relationship was provided by
Burtscher et al. (2008) who published a meta-analysis on the topic. A search of Pub Med
indexed articles from 1976-2007 was conducted using the following search terms:
intermittent hypoxia, simulated altitude, acute mountain sickness (AMS), prediction,
mountaineering, trekking, and hypoxic ventilatory response (HVR). In addition to the
search, the analysis included other relevant papers known to the author. In total, 16
papers were found, all of which looked at short-term hypoxic exposure. After review of
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the studies, it was concluded that due to the differing conditions and parameters of the
studies, no clear conclusions about SaO2 and AMS could be clearly derived. However, it
was stated that hypoxia was clearly responsible for AMS and that the degree of hypoxia,
when acutely exposed to high altitude, varies markedly between individual HVR.
Therefore, individual HVR may be considered as a predictor of tolerance to acute
hypoxia. Also stated were the summarized results leading to SaO2 values taken after
prolonged exposure to hypoxia as being found to closely relate with AMS susceptibility.
Upon compilation of these studies, it was concluded that a possible reason for the
occurrence of significance among these studies was the influence of an IPE that may
occur after prolonged hypoxic exposure. However, the question of how much time and
altitude are needed for this impairment remained unanswered.
Hoping to better understand how much exposure time and altitude are necessary
for SaO2 prediction of AMS, Roach et al. (1998) performed a study of asymptomatic
climbers coming through base camp at 4200 m on Denali with low SaO2. The hypothesis
presented was that these climbers would be more likely to develop AMS on further
ascent. In all, 102 climbers volunteered to participate in the study. The climbers had
flown to 2100 m, and then hiked to 4200 m in 9 ± 0.2 days to reach the camp. They
stayed at 4200 m before testing for 2.3 ± 0.2 days. The total time spent by climbers at
4200 m before ascent was 4.5 ± 0.5 days. During the study, climbers were above 4200 m
on summit attempt (6194 m) for 3 ± 0.2 days before returning for retesting. Upon
returning, climbers were interviewed about their symptoms while above 4200 m. Roach
et al. classified AMS using a clinical interview technique. A score of 2+ was classified as
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AMS. Throughout the study, SaO2 measurements were collected using ear oximetry. In
addition to SaO2, HVR rates were also measured. During the study 53% of climbers
reached the summit. Reported reasons for not reaching the summit included inclement
weather (45%), illness/other (35%), or involved in rescue (20%). Fifty-eight percent of
climbers had no AMS during ascent while 42% were diagnosed with AMS during ascent.
It was found that age related to AMS severity as 51% of those younger than 35 years had
AMS and only 5% of those older than 35 years developed AMS. The SaO2 at 4200 m for
all participants was 81.5 ± 4.4. The HVR rates were not predictive of AMS susceptibility,
leaving the relationship between these highly individualized responses and AMS in doubt
and uncertain. Finally, AMS was found to be significantly and negatively correlated with
SaO2 (r = -.48, p < .001). It was concluded that SaO2 as measured by ear oximetry was
predictive of subsequent AMS development. Subjects with SaO2 above 84% at this
altitude appeared to be immune to subsequent AMS. Using the 84% SaO2 cutoff
predicted 100% of those who would succumb to AMS, but 55% of all participants were
false positives, meaning that they were classified as susceptible and did not get sick
(score of 3+). Lowering the cut off to a SaO2 of 81.5% predicted 81% of those who
would succumb to AMS, and reduced the false positives to 26%. Also concluded was that
IPE may have been a cause of desaturation among participants and that this impairment
begins prior to the onset of the clinical symptoms of AMS, leaving the possibility of IPE
measurements to be highly related to AMS predictability.
In a study similar to Roach et al. (1998), SaO2 was observed as a possible
predictor for the occurrence of AMS (Koehle et al., 2010). This study looked at
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individuals who had traveled to 4380 m, making the last 2200 m of travel within the last
1-2 days. The LLSA was used to diagnose AMS and SaO2 was measured using a finger
pulse oximeter. Results from the 41 participants showed significantly lower SaO2 among
those with AMS as well as the SaO2 values being significantly correlated with the LLSA
scores. In further support of these findings, Tannheimer et al. (2009) also reported a
positive relationship between SaO2 and AMS. Each of these studies lends further
evidence toward the establishment of a relationship between SaO2 and AMS.
Contrary to some of the current research, there are several studies that still leave
the relationship between SaO2 and AMS to question. O'Connor, Dubowitz, and Bickler
(2004) conducted a study on Mt. Rainier with 169 participants, using the LLSA to score
AMS 30 min after resting at 3080 m. Arterial oxygen saturation measurements from each
participant were taken along with their heart rate. These two measurements, along with
other recorded variables, were compared for correlation to the prevalence of AMS.
Twenty-seven percent of the climbers were diagnosed with AMS during the study. The
mean SaO2 at 3080 m was reportedly 90

4% and the mean heart rate at 3080 m was 87

14 beats·min-1. Heart rate was the only variable found to significantly correlate with
AMS, as SaO2 was not a significant predictor. These data support other studies where
subject’s exposure to altitude was limited by study design to hours/days where no
significant relationship between SaO2 and AMS was found (Roeggla, Roeggla, Podolsky,
Wagner, & Laggner, 1996; Wagner et al., 2006).
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Summary

According to the recent research, it is possible that there is a relationship between
SaO2 and AMS. This relationship however, if present, is not well understood. It would
appear that SaO2 measurements taken 20-30 min after hypoxic exposure at 2300-4200 m
are a good predictor of AMS susceptibility and that HVR and IPE seem to be important
in the complex pathophysiological acclimatization process responsible for AMS. If this
relationship is to be better understood, researchers must decipher the pathway of
physiological response to hypoxemia and the timeline of AMS symptom onset.
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CHAPTER 3
METHODOLOGY

This chapter details the methods used in discovering how SaO2 relates to AMS
through the utilization of the LLSA and finger pulse oximetry. The chapter is organized
as follows: (a) participants, (b) setting, (c) procedure, and (d) data analysis.

Participants

Every climber arriving to the Piedra Grande mountain hut (4260 m) on Pico de
Orizaba intending to make a summit attempt was informed about the study and invited to
participate. Each was given the letter of information to read, as this served as the
informed consent. The letter was available in both English (Appendix A) and Spanish
(Appendix B). Climbers who did not understand either English or Spanish were excluded
from the study. Potential participants were encouraged to ask questions about the study
before agreeing to participate. The institutional review board of Utah State University
approved this study.

Setting

The study was conducted from the Piedra Grande climber's hut (4260 m) on the
north side of Pico de Orizaba (5640 m). Data collection from the hut spanned 8
consecutive days. As a popular climbing destination with easy access, this location
allowed for a large number of participants to take part in the study. This site was also
chosen for its optimal altitude for SaO2 measurements (Burtscher et al., 2008) as well as
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to correlate with other research conducted at a similar altitude (Roach et al., 1998). In
addition, this site provided a unique opportunity to study short-term field exposure to
high altitude as a result of the rapid rate at which the majority of climbers were able to
ascend. This unique timeline allowed for a short duration between the testing and
retesting and provided a better understanding of the timeline associated with the onset of
the physiological reactions that lead to AMS and their possible association with SaO2.

Procedures

Climbers traveled by truck from the village of Tlachichuca (2650 m) to the Piedra
Grande hut. As a result of this mode of travel they rapidly gained 2990 m of elevation
within about 2 hr. After being informed of the study and if willing to participate, they
were assigned an identification number. The date and time of each participant’s arrival to
the hut was noted. Within 30 min of exposure to 4260 m at the hut, data were collected.
The participants were seated while background and demographic information was
collected (Appendix C). Demographic characteristics included age, gender, height, and
weight. Historical information included altitude of residence, history of altitude illness,
number of ascents above 3000 m in the 10 days prior to this ascent, time above 3000 m in
the 10 days prior to this ascent, highest altitude achieved, and hours per week of training
in the months leading up to this ascent. Following this collection of information, the
LLSA for AMS (Appendices D and E) was administered. This was done by asking the
participants to rate a series of 5 symptoms based on their current individual level of
perceived severity. Each symptom was ranked on a scale ranging from “0 - None at all”
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to “3 - Severe.” After LLSA administration, pulse oximetry measurements were taken.
The finger pulse oximeter (SportStat, Nonin Medical Inc., Plymouth, MN) was placed on
the right index finger, and the SaO2 value remained stable for 1 min before being
recorded. Also, the heart rate (HR) was measured by the pulse oximeter while noting the
date and time of measurement. Following this initial data collection the climbers stayed
in the hut until their summit attempt. Immediately prior to their departure SaO2 and HR
measurements and the LLSA questionnaire were repeated. Again, the time and date of the
climbers’ departure was recorded. Immediately upon return from their summit attempt
the date and time of return was recorded. All physiological measurements and the LLSA
were repeated. This post ascent administration of the LLSA for AMS was phrased so as
to describe the climbers’ perceived symptoms of sickness throughout the duration of their
summit attempt above the hut (4260 m). In addition to the repetition of data collection as
before, additional ascent data were collected. Climbers were asked whether they reached
the summit, and whether they used acetazolamide or dexamethasone. If climbers were
unsuccessful with their summit attempts, they were asked to report a reason for not
reaching the summit. Possible reasons included: AMS, weather, fatigue, partner failure,
or other.
Data Analyses

In the process of data analyses, the total hypoxic exposure times and median
exposure times were calculated for the participants. Acute mountain sickness for each
participant was scored for all three data collection periods (arrival at 4260 m,
immediately prior to departure for the summit attempt, and immediately upon return from
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the summit attempt) using the LLSA. Positive diagnosis involved participants presenting
with a headache, at least one additional symptom, and a total symptom score ≥ 3. The
means for all descriptive data were then calculated. Independent t tests were performed to
determine if there was a significant mean difference in the preascent SaO2 of those who
did or did not experienced AMS during the ascent. Significance was based on p ≤ .05.
Following which, all collected variables were compared for significant difference
between those with and without AMS development using independent variable t testing.
Furthermore, an independent t test was conducted to determine if there was a significant
mean difference in SaO2, as measured preascent, between those who reached the summit
and those who turned back. Significance was also based on p ≤ .05. Next, independent
variable t tests were conducted to compare all other collected variables for significant
difference between those who reached the summit and those who did not. Then each of
the mean SaO2 measurements for participants with AMS and without for each of the three
collections, were compared for statistical difference using an independent t test. Lastly, a
change in SaO2 was calculated between different periods of data collection. The first
interval was from participants’ arrivals to the hut until their departure for the summit. The
second interval was from the participants’ departures for the summit until their return.
The third interval was calculated was from the participants’ arrivals to the hut until their
return from attempting to reach the summit. These differences were then compared
between those who developed AMS and those who did not using an independent t test for
statistical difference. All statistical analyses were done using the Statistical Package for
the Social Sciences (SPSS, version 17.0) or Microsoft Excel (Version 2004).
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CHAPTER 4
RESULTS

Throughout the duration of the data collection, 77 climbers arrived for their
attempt to summit the mountain. Of those 77 climbers, 2 declined to participate for
personal reasons, and 2 were omitted due to communication barriers. In total, 73 climbers
volunteered to participate in the study. Twelve of the 73 climbers were missing relevant
data. Missing data occurred due to unexpected complications such as an inability to
contact participants post ascent. In addition, 13 reported using acetazolamide or
dexamethasone to counter the effects of AMS. These individuals were excluded from the
statistical analyses as the use of these drugs has been shown to reduce AMS symptom
severity (Hackett & Roach, 2001). After all exclusions, there were 48 remaining
participants with complete data; 45 were male and 3 were female. The descriptive
statistics collected for the 48 remaining participants are summarized in Table 1.
In computing the time intervals between tests and retests, it was found that the
median time participants stayed at the hut before departing for the summit was 10 ± 13
hr. The median time for participants to reach the summit and return to the hut was 13.3 ±
4.8 hr. Of the participants, 29 (60.4%) successfully reached the summit. For those unable
to reach the summit, reasons given were; AMS being reported as the perceived cause in 8
(42.1%) cases, fatigue in 8 (42.1%) cases, partner failure in 2 (10.5%) cases, and other
reasons were cited in 1 (2.1%) case. In measuring AMS; 2 (4.2%) had AMS (LLSA)
upon arrival to the hut, 4 (8.3% ) had AMS (LLSA) immediately prior to departure for
the summit attempt, and 29 (60.4%) participants met the criteria for AMS (LLSA) during
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the ascent. In addition, 23 (79.3%) of these AMS cases during ascent were severe as they
scored ≥ 5 on the LLSA. The mean and standard deviations of the SaO2, HR, and LLSA
scores reported in Table 2 are separated between each of the three data collections. Table
3 identifies the number of participants diagnosed with or without AMS against those who
did or did not summit.

Table 1
Descriptive Statistics (N = 48)
Descriptive Statistic

Min

Max

M

SD

18

61

34.0

9.8

Height (cm)

148

190

176.0

7.6

Weight (kg)

45

100

75.2

11.2

BMI (kg/m2)

18

32

24.3

3.4

Altitude of residence (m)

0

3000

1446.7

866.0

Ascents above 3000 m in
last 10 days

0

10

1.4

1.9

Time (hr) above 3000 m in
last 10 days

0

240

22.0

42.0

2200

8850

5466.0

1176.6

0

25

8.6

7.1

Age (yr)

Highest altitude achieved
prior to this attempt (m)
Hours per week training

Note. Data are self-reported and body mass index (BMI) is calculated from self-reported
weight and height.
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Table 2
Heart Rates, Oxygen Saturations, and LLSA Scores (N = 48)
Upon Arrival to hut

Min

Max

M

SD

Heart rate (beats·min-1)

53

127

83.9

17.5

SaO2 (%)

74

94

86.3

4.3

0

3

0.7

0.9

Heart rate (beats·min-1)

58

118

91.0

14.5

SaO2 (%)

72

90

84.3

3.9

0

8

1.8

1.7

Heart rate (beats·min-1)

78

129

103.3

12.0

SaO2 (%)

70

93

84.7

5.7

0

13

5.3

3.3

LL AMS score

Departure for summit

LL AMS score

Return from summit

LL AMS score

Note. Scores and measurements are reported for the three periods of data collection that
were conducted throughout the study.
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Table 3
Acute Mountain Sickness and Summit Success Reported by Number of Climbers
Summit

No Summit

Total

AMS

16

13

29

No AMS

13

6

19

Total

29

19

48

From the t tests conducted, there was no significant difference (p = .90) found in
preascent SaO2 between those who experienced AMS during ascent (SaO2 = 84.3 ± 3.3%)
and those who did not (SaO2 = 84.2 ± 4.2%). Figure 1 displays the weak correlation (r = .14) associated with the preascent SaO2 measurements and subsequent AMS
development. There was also no significant difference (p = .18) in preascent SaO2
between those who reached the summit (SaO2 = 84.8 ± 3.7%) and those who did not
(SaO2 = 83.3 ± 4.0%). After performing these comparison tests for significance, all
demographic and historical variables were analyzed for any significant difference
between AMS and summit success groups. There were several variables found to be
significantly different (p < .05) between groups (Table 4). Age was found to be
significantly higher (p = .03) among those without future development of AMS.
Participant’s altitude of residence was another variable significantly different (p = .02)
between groups. Also, the highest altitude achieved prior to this attempt was found to be
significantly greater (p < .01) for those who did not get sick.
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Table 4
Mean Values of Significantly Different Characteristics Between Those With AMS and
Those Without
No AMS
M ± SD

AMS
M ± SD

p Value

Age (yr)

37.5 ± 10.5

31.4 ± 8.4

p = .03

Altitude of Residence (m)

1776 ± 718

1197 ± 881

p = .02

6029 ± 1059

4912 ± 966

p < .01

Highest Altitude Achieved (m)

Arterial Oxygen Saturation (%)

100

95
90
85
80
75

70
0

2

4

6

8

10

12

14

LLSA AMS Score

Figure 1. Relationship between arterial oxygen saturation prior to summit attempt and
LLSA AMS severity during summit attempt (r = -.14).
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While comparing all variables to participants’ summit success, it was found that
the number of ascents over 3000 m in the 10 days previous to this attempt was
significantly greater (p = .02) for those who successfully reached the summit than those
who did not. Participants who reached the summit had ascended an average of 1.8 ± 2.1
peaks while those who were unsuccessful had only ascended an average of 0.6 ± 1.2
peaks in the 10 days prior to this attempt. The number of hours spent above 3000 m in
the 10 days previous to this study was another variable found to be significantly greater
(p = .02) for those who found summit success. Participants who reached the summit had
spent an average of 31.8 ± 49.6 hr above 3000 m while those who did not had only spent
an average of 4.7 ± 14.5 hr. In addition, highest altitude ever achieved prior to this
expedition was found to be significantly higher (p = .04) among those who successfully
reached the summit. Those who had previously achieved an altitude of 5687.7 ± 1016.6
m were successful while those who were not had only achieved an altitude of 5028.1 ±
1276.3 m. Lastly, heart rate as measured at the time of departure for the summit attempt
was significantly lower (p = .04) for those who would reach the summit. These
participants had an average HR at the time of departure of 87.6 ± 14.2 beats·min-1 while
those who did not reach the summit had an average HR of 96.1 ± 13.4 beats·min-1.
In order to further analyze AMS development and summit success, each SaO2
measurement was compared to a corresponding LLSA AMS score that was recorded at
the same time. Table 5 and Figure 2 show the average SaO2 measurements of those who
developed AMS and those who did not as they changed over the course of the study.
Arterial oxygen saturation and AMS were not significantly different (p = .94) when the
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participants arrived to the hut. They were also not significantly different (p = .58) prior to
participants’ departures for their summit attempts. Arterial oxygen saturation was
however significantly different (p = .04) between those with and without AMS in the
measurements recorded after participants’ summit attempts. Figure 3 shows this
correlation between SaO2 and AMS (r = -.21).
Following this comparison, the differences in a participant’s initial, preascent, and
post ascent measurements of SaO2 were calculated so as to view how a participant’s
change in oxygen saturation (ΔSaO2) over time would relate to AMS development
(Figure 4 & Table 6). It was found that all participants showed desaturating ΔSaO2 from
the time of their arrival to the time at which SaO2 was measured prior to ascent (ΔSaO2 =
-2.3 ± 3.3%). This desaturation was not significantly different (p = .71) between those
with or without later AMS onset. However, the ΔSaO2 between preascent and post ascent
was significantly different (p = .03) between those who developed AMS and those who
did not. The ΔSaO2 over the entire course of hypoxic exposure (conclusion of climb –
arrival at hut) was also significantly different (p = .03) between groups.
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Table 5
Mean Arterial Oxygen Saturation for Those Who Developed AMS and Those Who Did
Not
AMS
M ± SD

No AMS
M ± SD

p Value

Arrival to the Hut (%)

86.5 ± 2.1

86.3 ± 4.3

.94

Departure for the Summit (%)

85.3 ± 5.5

84.1 ± 3.7

.56

Return from Summit Attempt (%)

82.9 ± 6.9

86.5 ± 3.6

.04

Arterial Oxygen Saturation (%)

Note. Measurements are reported for the three periods of data collection that were
conducted throughout the study.

88
87
86
85
84
83
82
81
80
79
78

AMS

No AMS

Arrival to the Hut Departure for the Return from
Summit
Summit Attempt
Period of Data Collection

Figure 2. Progression of mean arterial oxygen saturations of participants who developed
AMS versus the saturations of those who did not throughout the study.
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Arterial Oxygen Saturation (%)

100

95
90
85
80
75

70
0

2

4

6

8

10

12

14

LLSA AMS Score
Figure 3. Relationship between post ascent arterial oxygen saturation and severity of
AMS (r = -.21).

Table 6
Mean Values of the Change in Arterial Oxygen Saturation (ΔSaO2) for Participants With
and Without AMS
AMS
M ± SD

No AMS
M ± SD

ΔSaO2 from Arrival to Departure for Summit (%)

-2.2 ± 3.5

-2.6 ± 3.0

ΔSaO2 from Departure for Summit to Return (%)

-0.7 ± 5.2

2.3 ± 3.2

ΔSaO2 from Arrival to Return from Summit Attempt (%)

-3.5 ± 5.8

0.2 ± 3.7

Note. ΔSaO2 is calculated by taking the differences of SaO2 measurements taken from
two different data collections during the study.

Change in Arterial Oxygen Saturation (%)
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5
4
3
2
1
0
-1
-2
-3
-4
-5

AMS
No AMS

ΔSaO2 from
Arrival to
Departure for
Summit (%)

ΔSaO2 from
ΔSaO2 from
Departure for Arrival to Return
Summit to Return from Summit
(%)
Attempt (%)

Difference Between Two Periods of Data Collection

Figure 4. Change in arterial oxygen saturation (∆SaO2) of participants who developed
AMS versus those who did not. There was a significant difference found between those
with AMS and those without in the second (p = .03) and third (p = .03) comparisons of
∆SaO2 measurements.
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CHAPTER 5
DISCUSSION

SaO2 and Summit Success
Of all the participants in this study, more than half of them reached the summit
successfully, but the preascent SaO2 of these participants was not significantly different
from those who were unsuccessful. These results were unexpected. It is possible that a
low SaO2 may be overcompensated by a high level of physical fitness among climbers
reaching the summit. Wagner et al. (2008) found that increasing the number of hours
spent training per week was related to a greater likelihood of reaching the summit. In
addition, the results of this study show heart rate was significantly lower, prior to ascent,
among those who reached the summit. These findings correlate well, as a low heart rate
can be a direct result of increased fitness. Each of these factors lends further support to
the argument of increasing fitness as a means of overcoming a possible low SaO2 during
a summit attempt.

Significance of Other Variables to Summit Success

After finding no relationship between SaO2 and summit success, it was logical to
look to other variables to explain the difference between participants who reached the
summit and those who did not. It was found that the number of ascents and the number of
hours spent above 3000 m in the 10 days previous to this study were significantly
different between participants who were successful and those who were not. This
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difference could be attributed to the relationship between recent ascents and
acclimatization, therefore, leading those with numerous recent attempts to be more
acclimatized and less likely to become sick. However, as AMS and summit success were
found to be unrelated, it is unlikely for this to be the solution. In addition to these
findings, the highest altitude ever achieved by participants as well as their heart rate as
measured at the time of departure for the summit attempt were also significantly different
between successful and nonsuccessful participants. All of these results point toward
participants’ level of mountaineering experience as being directly related to their success
on the mountain. This conclusion is strongly supported by current theories on successful
mountaineering (Pesce et al., 2005; Wagner et al., 2008). The recent number of ascents,
time above 3000 m in the 10 days previous to this study, and a greater personal record of
highest altitude achieved all describe participants who are avid climbers and familiar with
successful mountaineering.
In addition to finding a relationship between these variables and summit success,
it was interesting to note that there was not a significant relationship between AMS and
summit success. This lack of relationship implies that the symptoms of AMS did not stop
the experienced climber from reaching the summit. Other research concludes that this
occurrence is a result of the inherent characteristics of mountaineering causing it to be a
highly driven sport. Therefore, the individuals involved in mountaineering must be
equally driven. As a result of this drive, AMS does not seem to prevent motivated
climbers from reaching the summit (Davies et al., 2009; Pesce et al., 2005; Tsianos et al.,
2006; Wagner et al., 2008). This is not to say that ignoring the symptoms of AMS is the
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only way to successfully reach the summit of a mountain. Another interpretation of this
theory suggests that with experience, mountaineers become more familiar with knowing
how hard and how far they can safely push their personal physical limitations. Although
an experienced mountaineer may be aware of possible impending AMS symptoms, they
could be more adept at assessing whether they would be able to reach the summit and
safely return. Those lacking this experience may be more willing to err on the side of
caution by heeding their symptoms of AMS and return short of their goal. Whatever the
reasons for successfully reaching the summit, it is apparent from these results that neither
SaO2 nor AMS significantly influenced these participants’ ability to reach the summit. It
is also clear that individual level of fitness and experience played a crucial role in summit
success.

SaO2 and AMS
The results of the study indicate that there was no significant relationship between
preascent SaO2 measurements and the development of AMS upon further ascent. These
results were unexpected as they differ from current theories that recognize a significant
relationship between AMS and SaO2. It is important to recognize that there are many
variables, such as level of exertion, that have a strong tendency to reduce the reliability
and validity of pulse oximetry measurements (Ontario Ministry of Health, 1992).
Furthermore there are many variables that may have a significant influence on AMS
assessment such as participant’s level of machismo (Sobralske, 2006). These factors
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could have made considerable contributions toward finding no significance between SaO2
and AMS in this study.
Additional analysis of AMS and SaO2 from each of the three data collections,
however, revealed a bit more detail into this complicated relationship. Comparisons of
concurrent AMS assessments and SaO2 measurements for each of the first two data
collections did not show any significant difference. The third data collection, which
followed the participants’ hypoxic exposure during their summit attempt, did however
show a significant difference in the SaO2 of those with AMS compared to those without.
The linear comparison of these means is represented in Figure 2. The initial lack of a
significant relationship between AMS and SaO2 followed by the future progression of
these means toward significance could be in part due to two different physiological
responses to hypoxia. These two responses are the HVR and IPE. Bartsch, Swenson,
Paul, Julg, and Hohenhaus (2002) conducted a study examining these acute ventilatory
responses to hypoxia in relation to AMS. From their study, it was found that HVR
attributed to a reduction in AMS scores from day 2 to 3 and was also associated with
substantial improvement in oxygenation and ventilation. Furthermore, individuals with
AMS showed lower, delayed HVR. From this study, IPE was reported to worsen with
continued exposure and that severe cases of AMS resulted from a combined effect of
HVR and IPE. Burtscher et al. (2004) also suggested HVR as a possible factor of
influence in short term hypoxic SaO2 changes as well as the role of IPE in long term
hypoxic exposure. These points were further illustrated by showing that AMS susceptible
individuals presented a low SaO2 when initially exposed to hypoxic conditions to which
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the researchers attributed a low HVR. To further support this theory, Roach et al. (1998)
attributed IPE as a possible cause for oxygen de saturation among the participants of their
study.
Each of these studies makes implications toward an important consideration for
the use of IPE and HVR as an explanation for these findings. This implication is the
potential difference in time for the onset of physiological oxygen saturation changes,
which are measured by pulse oximetry, and the onset of the cerebral edema that causes
the symptoms measured by the LLSA (O'Connor et al., 2004). This difference between
these two times of onset for such necessary responses implies that if SaO2 measurements
are to be predictive of AMS assessments, the point at which oxygen saturation responses
and cerebral responses to hypoxia overlap must be identified. The occurrence of an
overlapping point in such symptoms would provide an optimal period for the SaO2
prediction of future AMS susceptibility. This theory is also supported by conclusions
backing the use of SaO2 for AMS predictions and stating the necessity of adapting SaO2
measurements to different locations with resulting changes to exposure time while at
differing altitudes (Roach et al., 1998). Current research suggests that this duration of
hypoxic exposure is a major factor of influence in the fluctuation of this critical point
(Burtscher et al., 2008). Comparisons of the methods used in other recent studies reveals
a great deal about the possible processes occurring with AMS and this timeline associated
with symptom onset and exposure duration. The majority of studies reporting a
significant relationship between SaO2 and AMS were either conducted after a prolonged
hypoxic exposure or were a result of comparing SaO2 measurements with immediate
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AMS assessments (Burtscher et al., 2004, 2008; Koehle et al., 2010; Roach et al., 1998;
Tannheimer et al., 2009). Studies finding no relationship between AMS and SaO2
involved the measuring of SaO2 and AMS after a short hypoxic exposure (O'Connor et
al., 2004; Roeggla et al., 1996; Wagner et al., 2006). These comparisons show that a
longer duration of hypoxic exposure may lead to a higher probability of finding a
significant relationship between SaO2 and AMS.
A combination of the effects of HVR and IPE can be compiled through viewing
the current theory of the physiological processes of AMS onset. Hackett and Roach
(2001) provide a detailed description that lends a great deal of insight into the time line
necessary for SaO2 assessment of AMS. Apparent in their description, the authors
showed two periods of hypoxia, the first resulting from the initial environmental
exposure. This exposure elicits the immediate responses associated with hypoxia
including the variable HVR. The second period of hypoxia is referred to as an
exaggerated hypoxia. This level of hypoxia is apparently due to further compounding
effects of physiological responses on top of the initial external, environmental exposure
and is mostly limited to the pulmonary system causing IPE. As the duration of hypoxic
exposure increases, these impaired pulmonary system responses progress toward the
cerebral effects of AMS such as an increase in cerebral blood volume and brain water
levels. This description seems to attribute initial symptoms of AMS to HVR and later
symptoms to IPE. Further evidence from this paper reports cases of mild to moderate
AMS showed no increased intracranial pressure. Therefore, initial AMS is not due to an
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increase in intracranial pressure but more likely to mild oxygen deprivation. Moderate to
severe AMS, however, showed cases of increased intracranial pressure.
Summarizing the combination of these ideas, it is possible to conclude that initial
hypoxic exposure causes a HVR among mountaineers. As HVR differs between
individuals (Burtscher et al., 2008), it can be assumed that those with a decline in HVR
may incur the initial mild symptoms of AMS as a result of minor oxygen deprivation. As
these initial symptoms presumably occur without the physiological cerebral edemic
responses assessed by the LLSA, this period of AMS is unrelated to SaO2 measurements.
Additionally, increasing the duration of hypoxic exposure can lead to an IPE (Roach et
al., 1998). This IPE may result in a concurrent oxygen desaturation measured by pulse
oximetry along with the cerebral responses assessed by the LLSA. This degree of
hypoxic exposure could represent the point at which symptom measurement and hypoxic
response overlap, thereby allowing for SaO2 measurements to be significantly related to
AMS.

Significance of Other Variables to AMS

In addition to these results, it was also found that age of participants, altitude of
residence, highest altitude ever achieved before this attempt by participants, and SaO2 as
measured after ascent were all significantly different between participants with and
without the development of AMS. Age has often been associated with susceptibility to
AMS (Roach et al., 1998; Wagner et al., 2006, 2008). Altitude of residence could relate
with AMS development due to the effects of living and training at higher altitude toward
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an increased base level of acclimatization and improved performance while at altitude
(Levine & Stray-Gunderson, 1997; Stray-Gunderson, Chapman, & Levine, 2001).
Highest altitude achieved prior to this attempt could relate in the same manner to AMS as
was previously presented toward the association with summit success in that those with a
history of high ascents tend to be the more experienced climbers. With experience comes
a familiarity to the symptoms of AMS along with a possible desensitization to their
effects. As a result, when asked about the severity of their symptoms, experienced
climbers may respond lightly with the sense of having experienced a lot worse on
previous trips. This familiarity could affect the assessment of AMS when using the
LLSA.

Conclusion

Arterial oxygen saturation measurements were found to be unrelated to the onset
of AMS and therefore, SaO2 does not appear to be a reliable tool for the prediction of
AMS susceptibility. In addition, SaO2 measurements were not related to a mountaineer’s
ability to successfully reach the summit. Based on these findings, it can be concluded that
SaO2 is not useful for predicting summit success among mountaineers. The reliability and
validity of pulse oximetry measurements and participant’s level of machismo are most
likely significant contributors to the complex relationship of SaO2 and AMS found in this
study. There are also a great number of other uncontrolled variables that create a
complicated interplay of external environmental variables and internal physiological
characteristics. Further research is needed to better understand these intricately
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overlapping variables if SaO2 is to be applied to the prediction and diagnoses of AMS. It
may be that if this relationship does exist, there are simply too many factors to be
controlled in order to make these measurements useful. It is recommended that other
potential prediction methods and assessments be discovered.
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Dept. of Health, Physical Ed., and Recreation
7000 Old Main Hill
Logan, UT 84322-7000
Voice: (435) 797-1497

Date Created: November 11, 2008; Page 49 of 60
USU IRB Approved: 11/00/2008
Approval terminates: 11/00/2009
Protocol Number: 2180
IRB Password Protected per IRB Administrator

LETTER OF INFORMATION
Arterial Oxygen Saturation as a Predictor of Next-day Acute Mtn. Sickness or Summit
Success
Introduction/Purpose: Dr. Dale Wagner, assistant professor in the Health, Physical
Education and Recreation Department at Utah State University (USU), and his research
assistants (Jon Knott and Jack Fry) are conducting a study to determine if the arterial
oxygen saturation measurement (amount of oxygen in your blood) from a finger pulse
oximeter can predict acute mountain sickness or success in reaching the summit of Pico
de Orizaba. We anticipate approximately 50-100 participants in this research study, and
we invite you to participate.
Procedures: Upon arriving at the Piedra Grande Hut, you will be asked a few basic
personal questions (e.g., age, height, weight). After sitting for about 3 minutes, your
heart rate and oxygen saturation will be measured with a finger pulse oximeter. The
oximeter is a noninvasive device that fits over the index finger similar to the machines
that measure heart rate commonly used in shopping malls and gyms. The pulse oximeter
measurement will be repeated 3 times: 6-hours after the first measurement, just before
you depart for your summit attempt, and just after you return to the hut from your summit
attempt. You will also be asked about acute mountain sickness symptoms and whether or
not you reached the summit. The total time for your participation in this study will be
approximately 10 minutes.
Risks: Data will be collected with an interview from a questionnaire and from the finger
pulse oximeter; physical risks to participation in this study are minimal. The only
foreseeable risk is to your privacy, however only the interviewer will know your personal
information. Only the researchers associated with this study will have access to the data.
Benefits: Researchers hope to have a better understanding of what factors are
advantageous to reaching high mountain summits as well as determining which factors
predispose someone to acute mountain sickness. If we can tell by a number on a pulse
oximeter whether or not someone is likely to develop acute mountain sickness if ascent is
continued, then this would be a great benefit to the safety and success of future
mountaineers.
Explanation & Offer to Answer Questions: Dr. Wagner or one of the other affiliated
researchers has explained this study to you. You have been given the opportunity and
encouraged to ask questions. If you have other questions or research-related problems,
you may reach Dr. Wagner at (435) 797-8253 or by email at: dale.wagner@usu.edu
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Extra Costs & Payments: There is no cost for your participation in this study. You will
not be paid for participating in this study.
Voluntary Participation & Right to Withdraw: Your participation in this research is
entirely voluntary. You may refuse to participate or withdraw at any time without
consequence.
Confidentiality: Research records will be kept confidential, consistent with federal and
state regulations. Your data will be identified by a number, not by your name. Only the
research team will have access to the data, and it will be kept in a locked file cabinet in a
locked room.
Approval Statement: The Institutional Review Board for the protection of human
participants at USU has approved this research study. If you have any pertinent
questions or concerns about your rights or a research-related injury, you may contact the
IRB Administrator at (435) 797-0567 or email irb@usu.edu. If you have a concern or
complaint about the research and you would like to contact someone other than the
research team, you may contact the IRB Administrator to obtain information or to offer
input.
Investigator Statement: “I certify that the research study has been explained to the
individual, by me or my research staff, and that the individual understands the nature and
purpose, the possible risks, and benefits associated with taking part in this research study.
Any questions that have been raised have been answered.”

____________________________
Dr. Dale R. Wagner
Principal Investigator
(435) 797-8253

________________________
Date
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Dept. of Health, Physical Ed., and Recreation
7000 Old Main Hill
Logan, UT 84322-7000
Voice: (435) 797-1497

Fecha Creada: 11 Noviembre 2008; Página 52 de 60
USU IRB Aprobación: 11/00/2008
Aprobación Termina: 11/00/2009
Palabra de Pase por IRB Administradora

La Carta de Información
La Saturación Arterial del Oxígeno
Como un Pronosticador de Día-Siguiente Enfermedad Aguda de Montaña (EAM) o
Exito de Cumbre
Introducción/Propósito: Dr. Dale Wagner, el profesor agregado en el Departamento de
Salud, Educación Física y Recreación de la Universidad del Estado de Utah (Utah State
University) y sus ayudantes de investigación (Jon Knott y Jack Fry) estan haciendo un
estudio para determinar si la medida arterial de la saturación de oxígeno (la cantidad de
oxígeno en su sangre) de un oximeter de pulso de dedo puede predecir la Enfermedad
Aguda de Montaña (EAM) o el éxito de alcanzar la cumbre del Pico de Orizaba.
Anticipamos aproximadamente 50-100 participantes en este estudio de investigación, y le
invitamos a usted a participar.
Procedimientos: Al llegar a la Cabaña de Piedra Grande, usted será preguntado algunas
preguntas personales básicas (por ejemplo, su edad, estatura, y peso). Después de sentarse
por 3-5 minutos, el ritmo de su corazón y la saturación de su oxígeno serán medidos con
un oximeter de pulso de dedo. El oximeter es un aparato no invasor que se pone sobre el
dedo índice, y es semejante a las máquinas que miden el ritmo del corazón comúnmente
utilizado en centros comerciales y gimnasios. La medida de oximeter de pulso será
repetida 3 veces: de 6 horas después de la primera medida, poco antes de partir por su
tentativa de cumbre, y poco después de volver de su tentativa de cumbre a la cabaña.
Usted también estará preguntado por si a tenido síntomas de EAM y si usted alcanzó la
cumbre o no. El tiempo de su participación en este estudio será aproximadamente 10
minutos en total.
Riesgos: Los datos serán adquirido por medio de una entrevista con un cuestionario y
del oximeter de pulso de dedo; los riesgos físicos de participación en este estudio son
insignificantes. El único riesgo previsible es el de su privacidad. Sin embargo solamente
el entrevistador sabrá su información personal. Solamente los investigadores asociados
con este estudio tendrán acceso a los datos.
Beneficios: Por medio de esta investigación, esperamos obtener una comprensión
mejorada de cuales factores son ventajosos al alcanzar las cumbres altas de las montañas
y también determinar cuáles factores predisponen a alguien al EAM. Si podemos
determinar por un número en un oximeter de pulso si alguien es probable o no a
desarrollar EAM si la subida se continua, entonces esto sería un gran beneficio a la
seguridad y el éxito de alpinistas en el futuro.
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Explicación y La Oferta para Contestar Preguntas
Dr. Wagner o uno de los otros investigadores afiliados le han explicado este estudio a
usted. A Usted se le ha dado la oportunidad y alentación al hacer preguntas. Si usted tiene
otras preguntas o problemas relacionados a esta investigación, usted puede contactar al
Dr. Wagner por teléfono a 435-797-8253 o por correo electrónico en
dale.wagner@usu.edu.
Cuestas y Pagos Adicionales: No hay costo a usted para participar en este estudio.
Usted no recibirá pago por su participación en este estudio.
Participación Voluntaria y El Derecho de Retirar
Su participación en esta investigación es enteramente voluntaria. Usted puede negarse a
participar o retirarse en cualquier momento sin consecuencia.
Confidencialidad: Los registros de la investigación serán mantenidos confidencial,
coherente con las regulaciones federales y del estado. Sus datos serán identificados por
un número, no por su nombre. Sólo el equipo de investigación tendrá acceso a los datos,
y serán mantenidos en un archivador cerrado con llave en un cuarto cerrado con llave.
Declaración de Aprobación: La Junta Institucional de la Revisión (IRB) para la
protección de participantes humanos en la Universidad del Estado de Utah (Utah State
University) ha aprobado a este estudio de investigación. Si usted tiene alguna pregunta
pertinente o concierne acerca de sus derechos o una herida de esta investigación, usted
puede contactar al Administrador de IRB en (435) 797-0567 o irb@usu.edu correo
electrónico. Si usted tiene un concierne o la queja acerca de la investigación y usted
querría contactar alguien de otra manera que el equipo de investigación, usted puede
contactar al Administrador de IRB para obtener información o para ofrecer comentario.
Declaración de Investigador: “Certifico que el estudio de investigación le ha sido
explicado al individuo, por mí o por mi personal investigador, y que el individuo
comprende la naturaleza y el propósito, los riesgos posibles, y los beneficios asociados
con tomar parte en este estudio de investigación. Todas las preguntas que se han hecho se
han resolvidas.”

_____________________________________
Dr. Dale R. Wagner
Principal Investigador
435-797-8253

________________________
Fecha
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Data Collection Form
__________
Participant #
Demographic Characteristics:
Age:

Gender:

Height:

(in)

Weight:

(lb)

Acclimatization History:
Altitude of Residence:

(ft)

History of altitude illness:

(0 = no, 1 = yes)

Number of ascents above 3000 m (10,000’) in 10 days prior to this ascent:
Approximate time above 3000 m (10,000’) in 10 days prior to this ascent:
h:min
Highest altitude ever achieved prior to this ascent:

(ft)

Hours/week of training in the month leading up to this ascent:
Pulse Oximetry & AMS Data:
Arrival at Piedra Grande Hut (4250 m):
Pulse:

Date:

Time:

Date:

Time:

%SaO2 :

Return from summit attempt (4250 m):
Pulse:

Time:

%SaO2 :

Departure for summit attempt (4250 m):
Pulse:

Date:

%SaO2 :

Ascent Data:
Summit:

(0 = no, 1 = yes)

Use of Diamox/acetazolamide:

Reason for not reaching summit:
(1 = AMS, 2 = weather, 3 = fatigue, 4 = partner failure, 5 =

(0 = no, 1 = yes)

)
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Arrival (30 min) at Piedra Grande

Return from summit attempt

Lake Louise

Lake Louise

Headache:

Headache:

GI distress:

GI distress:

Fatigue:

Fatigue:

Dizzy:

Dizzy:

Sleep:

Sleep:

Departure for summit attempt
Lake Louise
Headache:
GI distress:
Fatigue:
Dizzy:
Sleep:
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Lake Louise AMS Self-Assessment

Headache:
0
None at all
1
A mild headache
2
Moderate headache
3
Severe headache, incapacitating
Gastrointestinal symptoms:
0
Good appetite
1
Poor appetite or nausea
2
Moderate nausea or vomiting
3
Severe, incapacitating nausea and vomiting
Fatigue and/or weakness:
0
Not tired or weak
1
Mild fatigue/weakness
2
Moderate fatigue/weakness
3
Severe fatigue/weakness, incapacitating
Dizziness/lightheadedness:
0
None
1
Mild
2
Moderate
3
Severe, incapacitating
Difficulty sleeping:
0
Slept as well as usual
1
Did not sleep as well as usual
2
Woke many times, poor night’s sleep
3
Could not sleep at all
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Appendix E: Lake Louise AMS Self-assessment Scale (Spanish)
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Lake Louise AMS Self-Assessment

Dolor de cabeza:
0
Ninguno
1
Leve; un poco
2
Moderado
3
Grave; incapacitar
Síntomas gastrointestinales:
0
Apetito bueno
1
Apetito malo o náusea
2
Náusea moderado or vomitar
3
Grave; incapacitar con náusea o vomitar
Fatigue o la debilidad:
0
Ninguno
1
Leve; un poco
2
Moderado
3
Grave; incapacitar
Vértigos:
0
Ninguno
1
Leve; un poco
2
Moderado
3
Grave; incapacitar
La dificultad que duerme:
0
Normal; durmió usual
1
No durmió así como usual
2
Despertó muchos veces, durmió malo
3
No podría dormir en todo

